Category	Primary Antibodies
Immunogen Target	leukocyte immunoglobulin-like receptor, subfamily A(with TM domain), member 2 (LILRA2)
Host	Rabbit
Reactivity	Human
Recommended Dilution	WB: 1:500-1:2000; IHC: 1:20-1:200
Clonality	polyclonal
Conjugation	Unconjugated
Isotype	IgG
Observed MW	53kd
Purity	≥95% as determined by SDS-PAGE
Purification	Immunogen affinity purified
Size 1	100µg
Form	liquid
Tested Applications	ELISA, WB, IHC
Storage	PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20℃ for 12 months(Avoid repeated freeze / thaw cycles.)
UniProt ID	Q8N149
Gene ID	11027
Alias	Leukocyte immunoglobulin-like receptor subfamily A member 2,ILT1,LIR7,CD85H,LIR-7,Immunoglobulin-like transcript 1,Leukocyte immunoglobulin-like receptor 7
Background	Antibody anti-LILRA2
Status	RUO
Note	Mol. Weight 53 kDa

Background

LILRA2, also known as Leukocyte Immunoglobulin-Like Receptor A2 (LILRA2) or CD85h, is a member of the immunoglobulin superfamily and part of the leukocyte immunoglobulin-like receptor (LILR) family. This receptor is encoded by the LILR gene cluster on chromosome 19q13.4, which is home to various immunoglobulin-like receptors involved in immune regulation. LILRA2 plays an activating role in immune response modulation and is predominantly expressed on monocytes, macrophages, and some other leukocyte subsets, such as granulocytes. It is essential in host defense, participating in immune responses to infections and modulating inflammation through cellular signaling pathways. The receptor interacts with a variety of ligands, likely including MHC class I molecules, which allows it to influence both innate and adaptive immunity. The immune-modulating role of LILRA2 makes it an essential subject of study in the context of immune responses and inflammation. Unlike other LILR members that may provide inhibitory signaling, LILRA2 is classified as an activating receptor, generally enhancing immune responses through its interaction with signaling adaptors that contain immunoreceptor tyrosine-based activation motifs (ITAMs). This activating function of LILRA2 contrasts with some members of the LILRB subfamily, which contain immunoreceptor tyrosine-based inhibitory motifs (ITIMs) and thus help suppress immune responses. Research has shown that aberrant expression or dysregulation of LILRA2 can contribute to inflammatory diseases, autoimmunity, and potentially cancer, making it a focal point for therapeutic interventions.

Productos relacionados

Leukocyte Immunoglobulin Like Receptor A2 (LILRA2) Antibody

Rabbit polyclonal antibody against LILRA2 protein. Immunogen region is Internal.…

Ver producto

Leukocyte Immunoglobulin Like Receptor A2 (LILRA2) Antibody

Leukocyte Ig-like receptors (LIRs) are a family of immunoreceptors expressed predominantly on monocytes and B cells and …

Ver producto

Human Leukocyte Immunoglobulin Like Receptor Subfamily A, Member 2 (LILRA2) Protein

Human Leukocyte Immunoglobulin Like Receptor Subfamily A, Member 2 (LILRA2) is a recombinant Human protein expressed in …

Ver producto